Novo Nordisk’s Phase 1/2 trial of amycretin, a next-generation amylin-targeting obesity injection, demonstrated substantial weight loss across multiple dose levels. However, overlapping efficacy curves and high side-effect rates blurred dose-response relationships typically expected in such studies. The highest dose (60 mg) yielded an average 24.3% weight reduction over 36 weeks versus 1.1% for placebo. While amycretin may offer superior efficacy to competitors, unclear dose optimization requires further clinical clarification, details presented at the ADA 2025 conference and reported in The Lancet.